A diagnosis of ductal carcinoma in situ (DCIS) might seem reassuring compared to invasive breast cancer, but recent research paints a more nuanced picture about this condition that affects roughly ...
Adjuvant tamoxifen may reduce recurrence risk for patients with ‘good-risk’ DCIS who forgo radiation
SAN ANTONIO – For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of ...
Hosted on MSN
Clinical trial: Adjuvant tamoxifen may reduce recurrence risk for patients with 'good-risk' DCIS who forgo radiation
For patients with "good-risk" ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results